Squamous cell anal carcinoma: Current therapeutic approaches
Valentina Zen, F. Bof, Rossana Intini, Giulia Maddalena et autres
0 citationsClinics and Research in Hepatology and Gastroenterology
Rossana Intini
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
108Publications signalées
1133Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Colorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersGenetic factors in colorectal cancerGastric Cancer Management and OutcomesLung Cancer Treatments and Mutations
Publications récentes
Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Andrea Pretta, Riccardo Giampieri, Andrea Bottelli, Ada Taravella et autres
0 citationsCancer Treatment Reviews
What is left in pMMR/MSS BRAF V600E metastatic colorectal cancer (mCRC)? Prognostic role of tumor sidedness and molecular co-mutations.
Eleonora Perissinotto, Rossana Intini, Giulia Maddalena, Riccardo Cerantola et autres
0 citationsJournal of Clinical Oncology
Impact of locoregional treatments in oligometastatic squamous cell anal carcinoma.
Valentina Zen, Giulia Maddalena, Rossana Intini, Federico Nichetti et autres
0 citationsJournal of Clinical Oncology
Neoadjuvant (NA) chemoradiotherapy (CTRT) plus avelumab (Ave) in locally advanced rectal cancer (LARC): 4-year outcomes of the phase II AVANA trial and their association with computational pathology.
G. Trovato, Maria Bensi, Daniele Rossini, Cecilia Villa et autres
0 citationsJournal of Clinical Oncology
Supplemental Figure 5 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taı̈eb, Marine Sroussi et autres
0 citations
Supplemental Figure 4 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taı̈eb, Marine Sroussi et autres
0 citations
Supplemental Figure 2 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taı̈eb, Marine Sroussi et autres
0 citations
Supplemental Figure 6 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taı̈eb, Marine Sroussi et autres
0 citations
Supplemental Figure 1 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taı̈eb, Marine Sroussi et autres
0 citations
Supplemental Figure 3 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taı̈eb, Marine Sroussi et autres
0 citations
Incidence of non-colorectal/endometrial malignancies in individuals with Lynch syndrome: a retrospective cohort study
Silvia Negro, Francesco Celotto, Francesca Schiavi, Marco Scarpa et autres
1 citationEClinicalMedicine
BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.